Corporate & Securities Law

EU Probes Pharmaceutical Industry

By David Fischer

According to the Wall Street Journal:

European Union investigators raided drug companies in several countries as the bloc’s antitrust watchdog launched a wide investigation of potentially anticompetitive practices in the industry.

Neelie Kroes, the EU antitrust chief, said the industry-wide inquiry would examine whether large companies are abusing their market power to prevent competitors from bringing new drugs to market, or whether companies were colluding to restrain competition.

AstraZeneca PLC, GlaxoSmithKline PLC, Sanofi-Aventis SA, and Pfizer Inc. said they were among the companies contacted, although the commission did not name the companies searched Tuesday and early Wednesday, nor where they were located.

The EU’s so-called sector inquiries are broad-brush examinations; they don’t necessarily lead regulators to bring antitrust cases, but can result in substantial fines. Recent sector inquiries have focused on energy markets and payment-card systems. Both eventually resulted in antitrust action — most recently in the EU’s declaring unlawful a type of interbank fee set by MasterCard.

…

The EU began the sector inquiry with unannounced inspections — triggering the first ones within hours of the commission’s decision Wednesday to authorize the inquiry. In earlier sector inquiries, EU officials had begun more politely, with requests for information.

Bloomberg also has a report.

The Commission’s press release is here; and the Commission’s FAQ on its antitrust sector inquiry into pharmaceuticals is here.

Full post as published by Antitrust Review on January 16, 2008 (boomark / email).